



**Intersect ENT Announces Positive Coverage Decision by Health Care Service Corporation**  
*Policy Update Facilitates Access to Nearly 14.7 Million Members*

Menlo Park, Calif. – May 4, 2015 – Intersect ENT, Inc. (NASDAQ: XENT), a company seeking to improve the quality of life for patients with ear, nose and throat conditions, today announced that Health Care Service Corporation (HCSC), the country’s largest customer owned health insurer, has updated its sinus surgery coverage policy. HCSC will now cover PROPEL® and PROPEL® mini, steroid releasing sinus implants, as “medically necessary” for patients meeting the criteria for endoscopic sinus surgery.

HCSC, the fourth-largest commercial payor in the United States, offers health insurance to nearly 14.7 million members through various subsidiaries including Blue Cross and Blue Shield of Illinois, Blue Cross and Blue Shield of Montana, Blue Cross and Blue Shield of New Mexico, Blue Cross and Blue Shield of Oklahoma, and BlueCross and Blue Shield of Texas.

The favorable coverage decision facilitates patient access to PROPEL and PROPEL mini, which are proven to improve clinical outcomes by reducing the need for medical and surgical intervention following surgery, with potential cost savings for the healthcare system.

“We applaud HCSC on their review and coverage decision, which recognizes the clinical and economic value of PROPEL and PROPEL mini as well as the quality of the clinical evidence supporting the products,” said Lisa Earnhardt, president and CEO of Intersect ENT. “This policy is an important step in a multi-year process to secure favorable coding and coverage for our products, and is consistent with coverage by other payors, including Blue Cross and Blue Shield of North Carolina, which recently updated its policy to cover PROPEL.”

**About Intersect ENT**

Intersect ENT, Inc. is dedicated to improving the quality of life for patients with ear, nose and throat conditions. The company markets two steroid releasing implants, PROPEL and PROPEL mini, clinically proven to improve surgical outcomes for patients with chronic sinusitis undergoing ethmoid sinus surgery. In addition, Intersect ENT is developing new steroid releasing implants designed to provide ENT physicians with even more customized options to treat patients with chronic sinusitis less invasively and more cost effectively. Chronic sinusitis is an inflammatory condition leading to debilitating symptoms and chronic infections, and is one of the most costly conditions to U.S. employers.

XENT-G

###

**Inquiries:**

**Media:**

Nicole Osmer  
650.454.0504

[nicole@nicoleosmer.com](mailto:nicole@nicoleosmer.com)

**Investors:**

Jeri Hilleman

650.641.2105

[ir@intersectENT.com](mailto:ir@intersectENT.com)